| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Theravance Biopharma (NASDAQ:TBPH) reported its Q4 earnings results on Monday, February 26, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Theravance Biopharma missed estimated earnings by -13.0%, reporting an EPS of $-0.17 versus an estimate of $-0.15.
Revenue was up $2.92 million from the same period last year.
Last quarter the company beat on EPS by $0.04 which was followed by a 5.0% increase in the share price the next day.
Here's a look at Theravance Biopharma's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.21 | -0.16 | -0.26 | -0.17 |
| EPS Actual | -0.17 | -0.13 | -0.24 | -0.21 |
| Revenue Estimate | 15.00M | 15.24M | 13.84M | 15.73M |
| Revenue Actual | 15.69M | 13.75M | 10.42M | 14.65M |
To track all earnings releases for Theravance Biopharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TBPH
